The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...

Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will ...

Job cuts at home-grown pharma companies like Arvinas and RallyBio and federal policies challenge CT biotech 'ecosystem' that ...

China is now setting the pace in life sciences R&D, conducting more clinical trials than the U.S. and licensing new ...

A new era of medical science is taking shape in Massachusetts. Our biotech companies are at work on a gene therapy that can cure deafness, treatments that slow the effects of aging, and a ...

East Midlands-based biotechnology company N4 Pharma has formed a new senior leadership team featuring consultants in drug ...

Sarcomatrix Therapeutics We are honored to present our progress at Start-Up Stadium and look forward to engaging with investors and partne ...

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...